Human cells with a 'built-in circuit' help prevent tumour growth

November 24, 2016, University of Southampton
The attached image shows microscope images of the engineered cells (nuclei in blue) with HIF-1 visualized (in red). In the left hand panel, cells are in hypoxia but no doxyxyclin is present, therefore HIF-1 remains active (red dots). In the right hand panel, the cells are grown in hypoxia and in the presence of doxyxyxlin, therefore the cyclic peptide inhibitor is produced and HIF-1 is inhibited, as demonstrated by the absence of the red dots. Credit: University of Southampton

Researchers at the University of Southampton have engineered cells with a 'built-in genetic circuit' that produces a molecule that inhibits the ability of tumours to survive and grow in their low oxygen environment.

The genetic circuit produces the machinery necessary for the production of a compound that inhibits a protein which has a significant and critical role in the growth and survival of . This results in the cancer cells being unable to survive in the low oxygen, low nutrient tumour micro-environment.

As tumours develop and grow, they rapidly outstrip the supply of oxygen delivered by existing blood vessels. This results in cancer cells needing to adapt to low oxygen environment.

To enable them to survive, adapt and grow in the low-oxygen or 'hypoxic' environments, tumours contain increased levels of a protein called Hypoxia-inducible factor 1 (HIF-1). HIF-1 senses reduced oxygen levels and triggers many changes in cellular function, including a changed metabolism and sending signals for the formation of new . It is thought that tumours primarily hijack the function of this protein (HIF-1) to survival and grow.

Professor Ali Tavassoli, who led the study with colleague Dr. Ishna Mistry, explains: "In an effort to better understand the role of HIF-1 in cancer, and to demonstrate the potential for inhibiting this protein in cancer therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF-1 inhibiting molecule when placed in a hypoxic environment.

"We've been able to show that the engineered cells produce the HIF-1 inhibitor, and this molecule goes on to inhibit HIF-1 function in cells, limiting the ability of these cells to survive and grow in a nutrient-limited environment as expected.

"In a wider sense, we have given these engineered cells the ability to fight back – to stop a key protein from functioning in cancer cells. This opens up the possibility for the production and use of sentinel circuits, which produce other bioactive compounds in response to environmental or cellular changes, to target a range of diseases including cancer."

The is incorporated onto the chromosome of a human cell line, which encodes the protein machinery required for the production of their cyclic peptide HIF-1 inhibitor. The production of the HIF-1 inhibitor occurs in response to hypoxia in these cells. The research team demonstrated that even when produced directly in cells, this molecule still prevents the HIF-1 signalling and the associated adaptation to hypoxia in these cells.

The next step for the researchers is to demonstrate the viability of this approach to the production and delivery of an anticancer molecule in a whole tumour model system.

Professor Tavassoli adds: "The main application for this work is that it eliminates the need for the synthesis of our inhibitor, so that biologists conducting research into HIF function can easily access our molecule and hopefully discover more about the role of HIF-1 in cancer. This will also let us understand whether inhibiting HIF-1 function alone is enough to block cancer growth in relevant models. Another interesting aspect to the work is that it demonstrates the possibility of adding new machinery to to enable them to make therapeutic agents in response to disease signals."

The study, which was funded by Cancer Research UK and the Engineering and Physical Sciences Research Council, is published in the journal ACS Synthetic Biology.

Explore further: A protein makes the difference

More information: Ishna N. Mistry et al. Reprogramming the Transcriptional Response to Hypoxia with a Chromosomally Encoded Cyclic Peptide HIF-1 Inhibitor, ACS Synthetic Biology (2016). DOI: 10.1021/acssynbio.6b00219

Related Stories

A protein makes the difference

October 18, 2016
When tumours develop they absorb oxygen and nutrients from the surrounding tissue. Once the tumour reaches a certain size, this is no longer enough to allow it to continue growing. It needs new blood vessels to deliver oxygen ...

Suffocating tumors could lead to new cancer drugs

July 26, 2013
Scientists have discovered a new molecule that prevents cancer cells from responding and surviving when starved of oxygen and which could be developed into new treatments for the disease, according to new research published ...

Searching for cancer's fingerprints gives clues to tumour growth

February 25, 2016
A University of Manchester study has shed light on a chain of events that allows tumour cells to thrive in tough environments, identifying potential new ways to diagnose and treat cancer.

Dying tumour cells release intracellular ions in a last-ditch attempt to block the immune system

September 15, 2016
Researchers at the National Cancer Institute in the USA and the Babraham Institute, UK, have discovered how a mineral ion leaked from tumour tissue as it dies acts to stop the work of anti-tumour immune cells. This discovery ...

Low oxygen, high risk: How tumors adapt to become more aggressive

August 8, 2016
One of the many reasons tumors are so difficult to treat is that they are able to adapt whenever they are exposed to unfavorable conditions. Hypoxia, or a lack of oxygen, is one example of a phenomenon that should weaken ...

Healthy cells 'collaborate' with tumors to help build new blood vessels

March 3, 2016
Healthy cells actively collaborate with tumours by creating a mesh of collagen that encourages cancer cells to build new blood vessels, a new study shows.

Recommended for you

Compound in citrus oil could reduce dry mouth in head, neck cancer patients

May 21, 2018
A compound found in citrus oils could help alleviate dry mouth caused by radiation therapy in head and neck cancer patients, according to a new study by researchers at the Stanford University School of Medicine.

Ice cream funds research showing new strategy against thyroid cancer

May 21, 2018
Anaplastic thyroid cancer is almost uniformly fatal, with an average lifespan of about 5 months after diagnosis. And standard treatment for the condition includes 7 weeks of radiation, often along with chemotherapy.

Bladder cancer model could pave the way for better drug efficacy studies

May 21, 2018
Understanding that not all bladder cancers are the same, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have created a tool that may help them to uncover why only a fraction of patients ...

Breath test breakthrough for early diagnosis of oesophageal and gastric cancer

May 18, 2018
A breath test can successfully detect oesophageal and gastric cancer and could be used as a first-line test for patients, say researchers.

MR spectroscopy imaging reveals effects of targeted treatment of mutant IDH1 gliomas

May 18, 2018
Using a novel imaging method, a Massachusetts General Hospital (MGH) research team is investigating the mechanisms behind a potential targeted treatment for a subtype of the deadly brains tumors called gliomas. In their report ...

Particle shows promise to prevent the spread of triple-negative breast cancer

May 18, 2018
USC researchers have pinpointed a remedy to prevent the spread of triple-negative breast cancer. Metastatic breast cancer is a leading cause of death for women. The findings appear today in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.